Insulin glargine: a long-acting insulin for diabetes mellitus
Garces K
Record ID 32002000447
English, French
Authors' objectives:
To summarize the available information on the use of insulin glargine (Lantus(TM), manufactured by Aventis Pharma) to treat patients over 17 years of age with type 1 or type 2 diabetes mellitus who require long-acting insulin control of hyperglycemia.
Authors' recommendations:
Insulin glargine is a treatment option for patients with type 1 diabetes mellitus. The evidence supporting its use over NPH insulin is limited, so the use of the drug versus alternatives may be limited to patient and physician preferences.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Diabetes Mellitus, Type 1
- Insulin
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.